Total Payments
$81,881
2024 Payments
$16,075
Companies
7
Transactions
122
Medicare Patients
958
Medicare Billing
$216,772
Payment Breakdown by Category
Other$55,793 (68.1%)
Consulting$13,515 (16.5%)
Travel$9,982 (12.2%)
Food & Beverage$2,582 (3.2%)
Education$10.20 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,093 | 30 | 61.2% |
| Consulting Fee | $13,515 | 5 | 16.5% |
| Travel and Lodging | $9,982 | 40 | 12.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,850 | 1 | 3.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $2,850 | 1 | 3.5% |
| Food and Beverage | $2,582 | 44 | 3.2% |
| Education | $10.20 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BTG International, Inc. | $70,227 | 107 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $11,045 | 7 | $0 (2023) |
| Amgen Inc. | $190.39 | 3 | $0 (2018) |
| Otsuka America Pharmaceutical, Inc. | $142.71 | 2 | $0 (2018) |
| GENZYME CORPORATION | $132.48 | 1 | $0 (2023) |
| Horizon Therapeutics plc | $121.50 | 1 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $22.26 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,075 | 23 | BTG International, Inc. ($16,053) |
| 2023 | $11,428 | 9 | Alexion Pharmaceuticals, Inc. ($10,760) |
| 2022 | $9,655 | 20 | BTG International, Inc. ($9,405) |
| 2020 | $5,400 | 12 | BTG INTERNATIONAL, INC. ($5,400) |
| 2019 | $17,512 | 28 | BTG International, Inc. ($17,391) |
| 2018 | $17,481 | 24 | BTG International, Inc. ($17,113) |
| 2017 | $4,330 | 6 | BTG International, Inc. ($4,330) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $22.26 | General |
| 08/02/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $519.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 08/02/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $226.44 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 07/30/2024 | BTG International, Inc. | VORAXAZE (Drug) | Food and Beverage | In-kind items and services | $120.42 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 06/18/2024 | BTG International, Inc. | VORAXAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 06/13/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $228.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 06/03/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $70.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 05/16/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $254.96 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 05/15/2024 | BTG International, Inc. | VORAXAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,712.50 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 05/10/2024 | BTG International, Inc. | VORAXAZE (Drug) | Food and Beverage | In-kind items and services | $100.13 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 04/27/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $633.88 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 04/26/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $110.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 04/26/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $35.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 04/24/2024 | BTG International, Inc. | VORAXAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 04/20/2024 | BTG International, Inc. | VORAXAZE (Drug) | Food and Beverage | In-kind items and services | $123.57 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 04/18/2024 | BTG International, Inc. | VORAXAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $875.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 04/04/2024 | BTG International, Inc. | VORAXAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 04/04/2024 | BTG International, Inc. | VORAXAZE (Biological) | Consulting Fee | Cash or cash equivalent | $1,225.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 03/23/2024 | BTG International, Inc. | VORAXAZE (Drug) | Food and Beverage | In-kind items and services | $119.74 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 03/22/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $238.66 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 02/14/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $790.86 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 02/13/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $110.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 02/13/2024 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $35.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 10/14/2023 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $10,050.00 | General |
| Category: Rare Disease | ||||||
| 10/14/2023 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $67.59 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 171 | 406 | $299,677 | $43,626 |
| 2022 | 5 | 187 | 498 | $443,427 | $55,366 |
| 2021 | 6 | 353 | 693 | $415,072 | $70,152 |
| 2020 | 4 | 247 | 494 | $161,580 | $47,628 |
Total Patients
958
Total Services
2,091
Medicare Billing
$216,772
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 25 | 93 | $205,716 | $16,147 | 7.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 69 | 166 | $46,978 | $15,849 | 33.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 62 | $12,400 | $4,026 | 32.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 26 | $13,494 | $3,528 | 26.1% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 17 | 46 | $16,422 | $2,693 | 16.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $4,667 | $1,384 | 29.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 46 | 153 | $338,436 | $26,783 | 7.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 78 | 265 | $74,995 | $20,820 | 27.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 36 | $18,684 | $5,254 | 28.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 13 | 28 | $5,600 | $1,604 | 28.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 15 | 16 | $5,712 | $905.47 | 15.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 153 | 386 | $109,238 | $31,934 | 29.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 49 | 110 | $228,723 | $19,768 | 8.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 59 | 61 | $31,659 | $10,031 | 31.7% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 47 | 90 | $32,130 | $5,212 | 16.2% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 25 | 26 | $9,542 | $2,079 | 21.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 20 | 20 | $3,780 | $1,127 | 29.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 133 | 345 | $97,635 | $29,953 | 30.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 72 | 79 | $40,971 | $13,354 | 32.6% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2020 | 30 | 58 | $20,706 | $3,587 | 17.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 12 | 12 | $2,268 | $734.88 | 32.4% |
About Dr. Jaya Kala, MD
Dr. Jaya Kala, MD is a Nephrology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2010. The National Provider Identifier (NPI) number assigned to this provider is 1306158878.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jaya Kala, MD has received a total of $81,881 in payments from pharmaceutical and medical device companies, with $16,075 received in 2024. These payments were reported across 122 transactions from 7 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($50,093).
As a Medicare-enrolled provider, Kala has provided services to 958 Medicare beneficiaries, totaling 2,091 services with total Medicare billing of $216,772. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Houston, TX
- Active Since 07/12/2010
- Last Updated 06/15/2022
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1306158878
Products in Payments
- VORAXAZE (Drug) $60,954
- SOLIRIS (Biological) $10,740
- VISTOGARD-20 (Drug) $4,330
- CROFAB (Drug) $3,718
- VORAXAZE (Biological) $1,225
- Aranesp (Biological) $145.39
- CABLIVI (Biological) $132.48
- JYNARQUE (Drug) $121.83
- KRYSTEXXA (Biological) $121.50
- XGEVA (Biological) $45.00
- SOLIRIS (Drug) $35.00
- SAMSCA (Drug) $20.88
- ULTOMIRIS (Biological) $20.21
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Houston
Sreedhar Mandayam, M.d, M.D
Nephrology — Payments: $789,657
Nephrology $789,657
Dr. Christopher Kwoh, M.d, M.D
Nephrology — Payments: $420,843
Nephrology $420,843
Dr. Maher Bishara, M.d, M.D
Nephrology — Payments: $119,839
Nephrology $119,839
Rajeev Raghavan, Md, MD
Nephrology — Payments: $119,615
Nephrology $119,615
Dr. Horacio Adrogue, Md, MD
Nephrology — Payments: $102,891
Nephrology $102,891
Dr. Kevin Erickson, M.d, M.D
Nephrology — Payments: $78,746
Nephrology $78,746